Literature DB >> 33465660

Fasting plasma glucose and subsequent cardiovascular disease among young adults: Analysis of a nationwide epidemiological database.

Hidehiro Kaneko1, Hidetaka Itoh2, Hiroyuki Kiriyama2, Tatsuya Kamon2, Katsuhito Fujiu3, Kojiro Morita4, Nobuaki Michihata5, Taisuke Jo5, Norifumi Takeda2, Hiroyuki Morita2, Hideo Yasunaga6, Issei Komuro2.   

Abstract

BACKGROUND AND AIMS: Using a nationwide epidemiological database, we aimed to clarify the association of fasting plasma glucose (FPG) with subsequent cardiovascular disease (CVD) risk among young adults. METHODS AND
RESULTS: Medical records of 1,180,062 young adults (20-49 years old) without a prior history of CVD and who were not taking antidiabetic medications were extracted from the Japan Medical Data Center. We categorized the study population into four groups: normal, FPG level<100 mg/dL (1,007,747 individuals), normal-high, FPG level of 100-109 mg/dL (126,602 individuals), impaired fasting glucose (IFG), FPG level of 110-125 mg/dL (32,451 individuals), and diabetes mellitus (DM), FPG level ≥126 mg/dL (13,262 individuals). The mean age was 39.7 ± 6.9 years, and 57.0% of the study population were men. Mean follow-up period was 1201 ± 905 days on average. Multivariable Cox regression analysis showed that IFG (hazard ratio [HR]; 1.38) and DM (HR; 2.09) increased the risk of myocardial infarction. Normal-high (HR; 1.11), IFG (HR; 1.18), and DM (HR; 1.59) groups had an elevated angina pectoris risk. DM (HR; 1.31) increased the risk of stroke compared to normal FPG levels. Normal-high levels (HR; 1.10), IFG (HR; 1.22) and DM (HR; 1.58) elevated the risk of heart failure. DM (HR; 1.69) increased the risk of atrial fibrillation.
CONCLUSIONS: Our analysis of a nationwide epidemiological database demonstrated a close association of the FPG category with subsequent CVD risk. Our results exemplify the importance of optimal FPG maintenance for the primary prevention of CVD in young adults.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diabetes mellitus; Hyperglycemia; Preventive cardiology; Young adult

Mesh:

Substances:

Year:  2021        PMID: 33465660     DOI: 10.1016/j.atherosclerosis.2020.12.024

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  Change in Cardiovascular Health Metrics and Risk for Proteinuria Development: Analysis of a Nationwide Population-Based Database.

Authors:  Yuta Suzuki; Hidehiro Kaneko; Akira Okada; Hidetaka Itoh; Kojiro Morita; Katsuhito Fujiu; Nobuaki Michihata; Taisuke Jo; Norifumi Takeda; Hiroyuki Morita; Satoko Yamaguchi; Kentaro Kamiya; Atsuhiko Matsunaga; Junya Ako; Akira Fukui; Akira Nishiyama; Takashi Yokoo; Koichi Node; Toshimasa Yamauchi; Masaomi Nangaku; Hideo Yasunaga; Issei Komuro
Journal:  Am J Nephrol       Date:  2022-03-08       Impact factor: 3.754

2.  Prediction model for the onset risk of impaired fasting glucose: a 10-year longitudinal retrospective cohort health check-up study.

Authors:  Yuqi Wang; Liangxu Wang; Yanli Su; Li Zhong; Bin Peng
Journal:  BMC Endocr Disord       Date:  2021-10-22       Impact factor: 2.763

3.  Sex Differences in Temporal Trends of Cardiovascular Health in Young US Adults.

Authors:  So Mi Jemma Cho; Sara Haidermota; Michael C Honigberg; Pradeep Natarajan
Journal:  J Am Heart Assoc       Date:  2022-06-02       Impact factor: 6.106

4.  Impact of Glucose Tolerance and Its Change on Incident Proteinuria: Analysis of a Nationwide Population-Based Dataset.

Authors:  Yuta Suzuki; Hidehiro Kaneko; Akira Okada; Hidetaka Itoh; Katsuhito Fujiu; Nobuaki Michihata; Taisuke Jo; Norifumi Takeda; Hiroyuki Morita; Satoko Yamaguchi; Kentaro Kamiya; Atsuhiko Matsunaga; Junya Ako; Koichi Node; Toshimasa Yamauchi; Masaomi Nangaku; Hideo Yasunaga; Issei Komuro
Journal:  Am J Nephrol       Date:  2022-03-09       Impact factor: 4.605

5.  Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.

Authors:  Yuta Suzuki; Hidehiro Kaneko; Akira Okada; Hidetaka Itoh; Satoshi Matsuoka; Katsuhito Fujiu; Nobuaki Michihata; Taisuke Jo; Norifumi Takeda; Hiroyuki Morita; Kentaro Kamiya; Atsuhiko Matsunaga; Junya Ako; Koichi Node; Hideo Yasunaga; Issei Komuro
Journal:  Cardiovasc Diabetol       Date:  2022-05-18       Impact factor: 8.949

Review 6.  Red Yeast Rice Preparations Reduce Mortality, Major Cardiovascular Adverse Events, and Risk Factors for Metabolic Syndrome: A Systematic Review and Meta-analysis.

Authors:  Rong Yuan; Yahui Yuan; Lidan Wang; Qiqi Xin; Ya Wang; Weili Shi; Yu Miao; Sean Xiao Leng; Keji Chen; Weihong Cong
Journal:  Front Pharmacol       Date:  2022-02-21       Impact factor: 5.810

7.  Neutrophil to high-density lipoprotein cholesterol ratio predicts adverse cardiovascular outcomes in subjects with pre-diabetes: a large cohort study from China.

Authors:  Shuo-Lin Liu; Bao-Yu Feng; Qi-Rui Song; Ying-Mei Zhang; Shuo-Ling Wu; Jun Cai
Journal:  Lipids Health Dis       Date:  2022-09-03       Impact factor: 4.315

8.  Association Between Fasting Hyperglycemia and New-Onset Atrial Fibrillation in Patients With Acute Myocardial Infarction and the Impact on Short- and Long-Term Prognosis.

Authors:  Mingxing Li; Yingying Gao; Kai Guo; Zidi Wu; Yi Lao; Jiewen Li; Xuansheng Huang; Li Feng; Jianting Dong; Yong Yuan
Journal:  Front Cardiovasc Med       Date:  2021-07-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.